Hoechst Aktiengesellschaft

Behringwerke Aktiengesellschaft

Hoechst Japan Limited

Hans G Berscheid

Hans P Kraemer

Hans-Wolfram Fehlhaber

Dirk Bottger

Cenek Kolar

Peter Hermentin

Michael Paal

Dieter Hoffmann

Gerhard Huber

Jochen Knolle

Hiroshi Kitagawa

Anuschirwan Peyman

Hans-Harald Sedlacek

Werner Aretz

Irvin Winkler

Bimal N Ganguli

Hiroshi Okazaki

Manfred Gerken

Karl-Heinz Budt

Hiroshi Watanabe

Bernd Stowasser

Julia Gandhi

Harald Zilg

Gauknapalli C Reddy

Yukiko Tone

Ratan S Sood

Isamu Sugawara

Hitoko Numata

Toshiro Iwahashi

Shunji Senda

Akihiko Matsuo

Itsuo Kurobane

Akio Fukuda

Junko Usui

Etsuko Ohkouchi

Prodrug derivatives of enzyme inhibitors having hydroxyl groups, a

The present invention relates to anthracycline derivatives of the formula I ##STR1## in which at least one of the two substitutents R.sub.1 and R.sub.2 represents an N-oxidized sugar or an N-oxidized sugar combination, and a chemical process for the preparation of these compounds and their use as medicaments for the treatment of malignant tumors.

Anthracyclinone glycosides containing an n-oxidized sugar

Cytorhodin S derivatives, especially cytorhodin S-immunoglobulin complexes are disclosed. Cytorhodin S possesses very high anticancer activity, but the complexes act more selectively on cancer cells and are more useful as an anticancer agent. New intermediate derivatives are also useful as an anticancer agent.

Cytorhodin S derivatives and a process for their preparation

The invention relates to new anthracycline derivatives having cytostatic activity and the general formula I, which are optionally in the form of a salt of an inorganic or organic acid, ##STR1## in which the substituents have the following meaning: R.sup.1 is hydrogen or a hydroxyl group,

Anthracycline derivatives having cytostatic activity

The invention relates to new anthracycline derivatives having cytostatic activity and the general formula I ##STR1## in which the radicals R.sup.1 is hydrogen or a hydroxyl group, R.sup.2 is hydrogen or a hydroxyl group or a structure of the formula II, and R.sup.3 is a hydroxyl group or a structure of the formula II ##STR2## in which R.sup.4 is an aliphatic or aromatic acyl group, with the proviso that at least one of the radicals R.sup.2 and R.sup.3 has a structure of the formula II, which are optionally in the form of a salt of an inorganic or organic acid, as well as to the process for the preparation thereof, and to the use thereof in pharmaceuticals.

The present invention relates to anthracycline derivatives and a process for their preparation. The compounds are distinguished by a high cytostatic activity and can therefore be used as medicaments with an anti-tumor action.

Anthracycline tetrasaccharides

The present invention relates to anthracyclin derivatives of the formula I ##STR1## in which R.sub.1 and R.sub.2 are identical or different and represent the sugar residue Roa (L--rhodosamine) of the formula ##STR2## or the sugar combination Roa--dF.dbd.CinB (dF=2-deoxy-L-fucose; CinB.dbd.L-cinerulose B) of the formula ##STR3## The invention furthermore relates to a process for the preparation of the above compounds of the formula I, and to their use as cytostatic agents.

Anthracyclin derivatives

The present invention relates to the micro-organism Streptomyces purpurascens (DSM 2658), its mutants and variants, a process for the preparation of anthracycline derivatives by fermentation of these cultures and to the anthracycline derivatives themselves. The new compounds are distinguished by antibacterial activity and, in addition, they act against various types of tumors.

Anthracycline derivatives and their use as cytostatics

Growing community of inventors

Schwalbach am Taunus, Germany

Hans G Berscheid